Atrial natriuretic paptide (ANP) inhibits H2O2-induced increases in pulmonary vascular permeability.
スポンサーリンク
概要
- 論文の詳細を見る
Increase in pulmonary vascular permeability by oxygen free radicals derived from neutrophils participates deeply in the pathophysiology of acute lung injury such as ARDS. Cyclic AMP restrains hyperpermeability of pulmonary vasculature in previous studies using? isolated perfused lungs, and endothelial cell monolayers. Cyclic GMP is also supposed to have the similar action. Atrial natriuretic peptide (ANP) increases intracellular cGMP content through a receptor on the cell surface. ANP is applied for the treatment of a heart failure, because its Na-diuretic effect and dilating effect on blood vessel reduce prelord and afterload of the heart. We paid attention for ANP to increase intracellular cGMP content and examined the action of ANP to inhibit H<SUB>2</SUB>O<SUB>2</SUB>-induced hyperpermeability of pulmonary vasculature. We used isolated perfused lungs of rabbit, and H<SUB>2</SUB>O<SUB>2</SUB> was administered at dose of 100 μM, 200 μM, 500 μM. Left atrial pressure (Pla), pulmonary artery pressure (Ppa) and lung weight gain (ΔW) were measured. Pulmonary capillary pressure was also measured with a double occlusion method and capillary filtration coefficient (Kfc) was calculated using a Paul's method. ΔW and Kfc were significantly increased dose-dependently after H<SUB>2</SUB>O<SUB>2</SUB> administration (p <0.05) . Increase of ΔW, Kfc and Ppa were significantly attenuated (p <0.05) by ANP. These results suggest that ANP attenuates the H<SUB>2</SUB>O<SUB>2</SUB>-induced hyper-permeability of pulmonary vascular and ANP is a useful therapeutic agent for the patient with hyperpermeability lung edema.
- 日本炎症・再生医学会の論文
日本炎症・再生医学会 | 論文
- 新規キノリノン誘導体TA-270の炎症性気道疾患に対する効果
- Salazosulphapyridine, Predonizolone の好中球機能に及ぼす影響と Sodium ferrous citrate との併用効果についての検討
- Sodium ferrous citrate の好中球機能に及ぼす影響
- Mesalazine(Pentasa) の好中球機能に及ぼす影響と Sodium ferrous citrate(SFC) との併用効果についての検討
- 非ウイルスベクターによる細胞標的法の開発